pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics of patient on statin and antiplatelet before propensity score matching

Clopidogrel (n=906)Cilostazol (n=79)Sarpogrelate (n=64)p-value
Age, years (mean±SD)62.1±9.964.9±8.161.7±8.90.066

Age, n (%)
 Less than 45 years34(3.8)0(0.00)1(1.6)0.046
 45-64 years468(51.7)33(41.8)39(60.9)
 65-74 years307(33.9)39(49.4)20(31.3)
 75 years and older97(10.7)7(8.9)4(6.3)
Male, n (%)615(67.9)51(64.6)32(50.0)0.013
CCI (mean+/-SD)0.12±0.580.19±0.680.08±0.410.327

Statin types, n (%)<.0001
 Atorvastatin363(40.1)44(55.7)27(42.2)0.026
 Rosuvastatin375(41.4)25(31.7)13(20.3)0.001
 Simvastatin107(11.8)3(3.8)7(10.9)0.095
 Pravastatin36(4.0)4(5.1)3(4.7)0.735
 Pitavastatin19(2.1)3(3.8)9(14.1)<0.001
 Fluvastatin6(0.7)0(0)5(7.8)<0.001

Comorbidities, n (%)
 Hypertension81 (8.9)7(8.9)4(6.3)0.763
 Heart failure2(0.2)0(0)0(0)1.000
 Diabetes mellitus, type 221 (2.3)4(5.1)1(1.6)0.253
 Chronic kidney disease13(1.4)0(0)0(0)0.831

Concomitant medications, n (%)
 Aspirin845(93.3)71(89.9)40(62.5)<0.001
 ACEI/ARB629(69.4)59(74.7)43(67.2)0.562
 Beta Blocker410(45.3)31 (39.2)23(35.9)0.227
 NDHP-CCB415(45.8)27(34.2)24(37.5)0.071
 DHP-CCB308(34.0)34(43.0)28(43.8)0.093
 Thiazide162(17.9)11(13.9)6(9.4)0.161
 Loop diuretics67(7.4)4(5.1)5(7.8)0.733
 Potassium sparing agents43(4.8)2(2.5)2(3.1)0.754
 Other lipid lowering agents135(14.9)7(8.9)8(12.5)0.310
 Antidiabetic agents235(25.9)32(40.5)21 (32.8)0.013

CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; N/DHP-CCB, non/dihydro- pyridine calcium channel blocker.

Korean J Clin Pharm 2019;29:254-66 https://doi.org/10.24304/kjcp.2019.29.4.254
© 2019 Korean J Clin Pharm